接受利拉鲁肽或格列美脲治疗的 2 型糖尿病患者的患者报告结局，两者均作为二甲双胍的附加治疗。
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
机构信息
Department of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus, Denmark.
出版信息
Prim Care Diabetes. 2010 Jul;4(2):113-7. doi: 10.1016/j.pcd.2010.04.001. Epub 2010 May 4.
PMID:20444662
Abstract
Patient-reported outcomes for liraglutide or glimepiride on metformin were investigated. Patients' treatment satisfaction on liraglutide was higher than with metformin alone and comparable with glimepiride+metformin. Patients perceived lower frequency of hypoglycaemia than glimepiride+metformin and lower frequency of hyperglycaemia than metformin. Impact of weight on quality of life did not differ.
摘要
研究了利拉鲁肽或格列美脲与二甲双胍联合治疗对患者报告结局的影响。与单独使用二甲双胍相比，患者对利拉鲁肽的治疗满意度更高，与格列美脲+二甲双胍相当。患者认为低血糖的发生频率低于格列美脲+二甲双胍，而高血糖的发生频率低于二甲双胍。体重对生活质量的影响没有差异。
Zotero 插件